IMARC Group has recently released a new research study titled “United States Biologics Market Size, Share, Trends and Forecast by Source, Product, Disease, Manufacturing and Region, 2025-2033” which offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.
Market Overview
The United States biologics market size was valued at USD 190.3 Billion in 2024 and is projected to reach USD 371.0 Billion by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033. This growth is driven by rapid adoption of bioprocessing technologies, expansion of biosimilars to improve affordability, and increased AI integration in biologics development, enhancing innovation and patient access.
Study Assumption Years
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
United States Biologics Market Key Takeaways
- Current Market Size: USD 190.3 Billion in 2024
- CAGR: 7.4% (2025-2033)
- Forecast Period: 2025-2033
- The market growth is primarily driven by the adoption of advanced bioprocessing technologies enhancing production efficiency and scalability.
- Biosimilars are expanding rapidly due to their cost-effective alternatives to branded biologics, increasing market competition.
- AI integration accelerates drug discovery, clinical trials, and manufacturing, improving timelines and outcomes.
- Supportive FDA frameworks and rising healthcare expenditure facilitate faster therapy approvals and wider patient access.
- Strategic partnerships, like Galapagos NV and Blood Centers of America, decentralize biologics manufacturing to improve scalability and delivery speed.
Sample Request Link: https://www.imarcgroup.com/united-states-biologics-market/requestsample
To get more information on this market, Request Sample
United States Biologics Market Growth Factors
The United States biologics market growth is propelled by rapid adoption of advanced bioprocessing technologies. These include single-use bioreactors, continuous manufacturing, and high-throughput screening systems that increase production efficiency and scalability. For instance, Rentschler Biopharma’s Milford facility, operational since July 11, 2024, features four 2,000L single-use bioreactors, doubling cGMP capacity for complex biologics. These technologies reduce costs while maintaining quality standards and improving accessibility. Automation and digital tools further optimize bioprocessing, resulting in consistent output with fewer errors. Biopharmaceutical companies invest heavily in upgrading facilities and refining production techniques, which are crucial drivers in the market.
The market is further expanded by the growing biosimilars segment, fueled by demand for affordable alternatives to branded biologics. The FDA’s Biosimilar Approval Pathway has streamlined market entry, increasing competition and lowering treatment costs. Biosimilars improve accessibility for chronic disease therapies, such as cancer and autoimmune disorders. For example, on July 2, 2024, Sobi initiated a rolling Biologics License Application submission for SEL-212, targeting chronic refractory gout. Pharmaceutical companies invest significantly in biosimilar R&D in response to expiring biologic patents. Increasing biosimilar adoption by providers and patients fosters market growth and spurs innovation.
Integration of artificial intelligence in biologics development is transforming the market by enhancing drug discovery, clinical trials, and manufacturing processes. AI platforms analyze extensive datasets to identify promising biologic candidates efficiently, reducing time and costs compared to traditional R&D. AI optimizes clinical trial patient recruitment, real-time monitoring, and outcome prediction, increasing trial success rates. In manufacturing, AI supports quality control, predictive maintenance, and workflow optimization. Collaborations between tech firms and biopharmaceutical companies accelerate these trends. The evolving AI applications in biologics development open possibilities for novel therapies and improved patient access.
United States Biologics Market Segmentation
Analysis by Source:
- Microbial: Microbial systems are vital in the U.S. biologics market, serving as effective hosts for recombinant proteins, enzymes, and vaccines. They offer rapid growth, cost-efficiency, and scalability, utilizing organisms such as E. coli and yeast, enhanced by synthetic biology and genetic engineering.
- Mammalian: Mammalian systems produce complex biologics like monoclonal antibodies, fusion proteins, and cell therapies. CHO (Chinese Hamster Ovary) cells dominate due to their superior post-translational modifications, bioactivity, and compatibility, supported by advanced bioreactors, crucial for therapies targeting cancer and autoimmune diseases.
- Others: Not provided in source.
Analysis by Product:
- Monoclonal Antibodies: Widely used for cancer, autoimmune diseases, and infections, offering targeted therapies with fewer side effects. Innovations include antibody-drug conjugates and bispecific antibodies, with significant investment and expanding applications.
- Vaccines: Growth driven by mRNA technology and pandemic preparedness, with successes like COVID-19 vaccines. Ongoing R&D in cancer and personalized vaccines, bolstered by immunization initiatives and government support.
- Recombinant Proteins: Used for diabetes, anemia, and growth disorders. Protein engineering advances enhance efficacy and stability. Biosimilars improve affordability and accessibility.
- Antisense, RNAi and Molecular Therapy: Not provided in source.
- Others: Not provided in source.
Analysis by Disease:
- Oncology: Leading segment due to high cancer incidence; therapies include monoclonal antibodies and immune checkpoint inhibitors. Progress in CAR-T cell therapy and personalized medicine is supported by strong clinical trials and funding.
- Immunological Disorders: Growing due to diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Cytokine inhibitors and TNF blockers improve management; biosimilars increase access.
- Cardiovascular Disorders: Gaining traction with monoclonal antibodies like PCSK9 inhibitors regulating cholesterol. Investments in rare cardiovascular biologics and regenerative therapies are enhancing the segment.
- Hematological Disorders: Not provided in source.
- Others: Not provided in source.
Analysis by Manufacturing:
- Outsourced: Increasing reliance on contract research and manufacturing organizations for cost-effective production, access to advanced technologies, and scalability, particularly for biosimilars and gene therapies.
- In-House: Essential for control over manufacturing, quality, and intellectual property. Large firms invest in advanced facilities for high-value biologics, balancing higher costs with workflow efficiency and innovation.
Regional Insights
The West region dominates biologics innovation in the U.S., particularly California, hosting Silicon Valley biotechnology companies and research institutions. This region excels in cutting-edge biologics like CAR-T cell therapies and mRNA vaccines, driven by robust venture capital funding and collaborations between startups and academia. The West also leads in personalized medicine and sustainability initiatives, positioning it at the forefront of shaping U.S. healthcare’s biologics future.
Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=20441&flag=C
Recent Developments & News
- On September 27, 2024, the FDA approved Dupixent (dupilumab) as the first biologic for inadequately controlled COPD with an eosinophilic phenotype. Phase 3 trials showed reductions in exacerbations by up to 34%, improved lung function, and better quality of life. Dupixent is under global review.
- On February 29, 2024, Biocon Biologics Ltd entered a settlement and license agreement with Janssen Biotech to commercialize Bmab 1200, a biosimilar to Stelara (Ustekinumab), in the U.S. from February 2025, pending FDA approval. This agreement resolves patent disputes and expands Biocon’s immunology franchise. Stelara was a USD 7 Billion medication in 2023.
Competitive Landscape
The market research report covers a comprehensive competitive landscape analysis including market structure, key player positioning, winning strategies, competitive dashboards, and company evaluation quadrants. Detailed profiles of all major companies have been provided.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
